Recent News Releases
For investor-related news, see our ASX releases here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Apr 29, 2021The label update is based on open label extension data from the landmark PATH (Polyneuropathy And Treatment with Hizentra) study
KING OF PRUSSIA, Pa. – April 29, 2021 – Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved a label update for Hizentra®...
-
Apr 28, 2021
CARE-HK in heart failure (HF) is the first global registry of around 5,000 patients with chronic HF who have or are at high risk for hyperkalemia (HK), in Europe and the US CARE-HK in HF is...
-
Apr 8, 2021
CSL remains committed to meeting its contracted arrangements with the Australian Government and AstraZeneca for locally produced AstraZeneca COVID-19 vaccines. We will continue our focused and...
Apr 2, 2021CSL continues to provide medicines to patients around the world. Safeguarding our people, patients and donors remains our top priority. As the COVID-19 pandemic evolves, CSL continues to provide...
-
Apr 2, 2021
Here is how CSL is working around the world with academia, industry and governments to combat the novel coronavirus COVID-19 CSL and AstraZeneca have agreed for CSL to manufacture approximately 50...